Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPC5 | Q9UL62 | 13/20 | 0.61 |
| ▸ | TRPC4 | Q9UBN4 | 2/20 | 0.61 |
| ▸ | TRPC1 | P48995 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | P2RX3 | P56373 | 6/20 | 0.45 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21332460 | 0.95 | TRPC5 (0.57) | TRPC5TRPC4TRPC1KCNH2P2RX3 | |
| SCHEMBL21332540 | 0.92 | TRPC5 (0.52) | TRPC5TRPC4TRPC1KCNH2P2RX3 | |
| SCHEMBL21345328 | 0.90 | TRPC5 (0.51) | TRPC5TRPC4TRPC1KCNH2P2RX3 | |
| SCHEMBL21345327 | 0.90 | TRPC5 (0.50) | TRPC5TRPC4TRPC1KCNH2P2RX3 | |
| SCHEMBL21345325 | 0.89 | TRPC5 (0.50) | TRPC5TRPC4TRPC1KCNH2P2RX3 | |
| SCHEMBL30980074 | 0.89 | TRPC5 (0.50) | TRPC5TRPC4TRPC1KCNH2P2RX3 | |
| SCHEMBL21332748 | 0.88 | TRPC5 (0.60) | TRPC5TRPC4TRPC1KCNH2P2RX3 | |
| SCHEMBL30642043 | 0.88 | TRPC5 (0.53) | TRPC5TRPC4TRPC1KCNH2P2RX3 | |
| SCHEMBL21345326 | 0.87 | TRPC5 (0.49) | TRPC5TRPC4TRPC1KCNH2PCSK9 | |
| SCHEMBL23142729 | 0.87 | TRPC5 (0.48) | TRPC5TRPC4TRPC1KCNH2P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3761989-B1 | IMIDAZODIAZEPINEDIONES AND METHODS OF USE THEREOF | GFB ABC LLC (US) | 2026-05-13 | — | — | EP | disclosed |
| US-12466834-B2 | Imidazodiazepinediones and methods of use thereof | GFB (ABC), LLC (US) | 2025-11-11 | — | — | US | disclosed |
| CN-118908961-A | Imidazodiazepine diketones and methods of use thereof | 金翅雀生物公司 | 2024-11-08 | — | — | CN | disclosed |
| CN-112351781-B | Imidazodiazepine diketones and methods of use thereof | 金翅雀生物公司 | 2024-07-02 | — | — | CN | disclosed |
| US-20230365575-A1 | IMIDAZODIAZEPINEDIONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2023-11-16 | — | — | US | disclosed |
| US-20230365575-A1 | IMIDAZODIAZEPINEDIONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2023-11-16 | — | — | US | disclosed |
| US-20230365575-A1 | IMIDAZODIAZEPINEDIONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2023-11-16 | — | — | US | disclosed |
| US-11623930-B2 | Imidazodiazepinediones and methods of use thereof | GOLDFINCH BIO, INC. (US) | 2023-04-11 | — | — | US | disclosed |
| US-11623930-B2 | Imidazodiazepinediones and methods of use thereof | GOLDFINCH BIO, INC. (US) | 2023-04-11 | — | — | US | disclosed |
| US-20210087200-A1 | IMIDAZODIAZEPINEDIONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2021-03-25 | — | — | US | disclosed |
| US-20210087200-A1 | IMIDAZODIAZEPINEDIONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2021-03-25 | — | — | US | disclosed |
| EP-3761989-A1 | IMIDAZODIAZEPINEDIONES AND METHODS OF USE THEREOF | Goldfinch Bio, Inc. (US) | 2021-01-13 | — | — | EP | disclosed |
| WO-2019173327-A1 | IMIDAZODIAZEPINEDIONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. (US) | 2019-09-12 | — | — | WO | disclosed |
| WO-2019173327-A1 | IMIDAZODIAZEPINEDIONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. (US) | 2019-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365575-A1 | IMIDAZODIAZEPINEDIONES AND METHODS OF USE THEREOF | REN, ATP6V1B1, GLS | TRPC5 1332/4885TRPC4 1226/4885TRPC1 2409/4885 |
| US-11623930-B2 | Imidazodiazepinediones and methods of use thereof | REN, ATP6V1B1, GLS | TRPC5 1332/4885TRPC4 1226/4885TRPC1 2409/4885 |
| US-20210087200-A1 | IMIDAZODIAZEPINEDIONES AND METHODS OF USE THEREOF | REN, ATP6V1B1, GLS | TRPC5 1332/4885TRPC4 1226/4885TRPC1 2409/4885 |
| US-12466834-B2 | Imidazodiazepinediones and methods of use thereof | REN, ATP6V1B1, GLS | TRPC5 1332/4885TRPC4 1226/4885TRPC1 2409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.